Skip to main content

Advertisement

Fig. 4 | Allergy, Asthma & Clinical Immunology

Fig. 4

From: The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option

Fig. 4

(Reprinted with permission from Berger et al. [130])

Least squares (LS) mean change from baseline in reflective total nasal symptom score (rTNSS; am + pm) per day when most children (n = 82; > 90%) rated their own symptoms following treatment with MP-AzeFlu or placebo, both one spray per nostril twice daily, for 14 days in children aged 6–11 years with moderate-severe SAR. MP-AzeFlu a novel formulation of an intranasal antihistamine, azelastine hydrochloride, and an intranasal corticosteroid, fluticasone propionate, in a single spray, SAR seasonal allergic rhinitis. *p ≤ 0.040 versus placebo

Back to article page